During the last session, Cocrystal Pharma Inc. (NASDAQ:COCP)’s traded shares were 0.18 million, with the beta value of the company hitting 0.73. At the end of the trading day, the stock’s price was $0.41, reflecting an intraday loss of -3.57% or -$0.01. The 52-week high for the COCP share is $1.23, that puts it down -200.0 from that peak though still a striking 14.63% gain since the share price plummeted to a 52-week low of $0.35. The company’s market capitalization is $39.69M, and the average intraday trading volume over the past 10 days was 0.15 million shares, and the average trade volume was 191.89K shares over the past three months.
Cocrystal Pharma Inc. (COCP) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. COCP has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.04.
Cocrystal Pharma Inc. (NASDAQ:COCP) trade information
Cocrystal Pharma Inc. (COCP) registered a -3.57% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.57% in intraday trading to $0.41 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 0.87%, and it has moved by -1.22% in 30 days. Based on these gigs, the overall price performance for the year is -62.50%. The short interest in Cocrystal Pharma Inc. (NASDAQ:COCP) is 0.16 million shares and it means that shorts have 1.07 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.50, which implies an increase of 90.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $5.00 respectively. As a result, COCP is trading at a discount of -1119.51% off the target high and -875.61% off the low.
Cocrystal Pharma Inc. (COCP) estimates and forecasts
Statistics show that Cocrystal Pharma Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Cocrystal Pharma Inc. (COCP) shares have gone down -25.07% during the last six months, with a year-to-date growth rate less than the industry average at -6.25% against 1.00.
Revenue for the current quarter is expected to be $80k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $80k by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 45.00%. While earnings are projected to return 8.10% in 2022.
Cocrystal Pharma Inc. is due to release its next quarterly earnings between March 15 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cocrystal Pharma Inc. (NASDAQ:COCP)’s Major holders
Cocrystal Pharma Inc. insiders own 15.89% of total outstanding shares while institutional holders control 21.45%, with the float percentage being 25.50%. Sabby Management, LLC is the largest shareholder of the company, while 40 institutions own stock in it. As of Mar 30, 2022, the company held over 5.61 million shares (or 18.75% of all shares), a total value of $3.09 million in shares.
The next largest institutional holding, with 3.27 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 10.94% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $1.8 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cocrystal Pharma Inc. (COCP) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.3 million shares. This amounts to just over 7.67 percent of the company’s overall shares, with a $1.26 million market value. The same data shows that the other fund manager holds slightly less at 0.84 million, or about 2.81% of the stock, which is worth about $0.46 million.